They’re different medicines, and in the UK they usually sit in different prescribing pathways.

Table of Contents

Same vs Different (fast answer)

Not the same drug: Mounjaro contains tirzepatide, Ozempic contains semaglutide.
Not the same indication: Ozempic is a diabetes medicine (type 2 diabetes). Using it for weight loss is generally considered off-label and has been highlighted in UK supply communications.
If your goal is weight loss: the cleaner UK pathway is to use an authorised weight-management medicine via clinical assessment (for MedCare, start at Mounjaro weight loss injection pen).

1) What each one actually is (active ingredient)

Mounjaro = tirzepatide

Mounjaro is the brand for tirzepatide a different active ingredient from Ozempic. If you want the plain-language definition first, use: What Is Mounjaro (Tirzepatide) for Weight Loss?.

Ozempic = semaglutide (GLP-1 analogue)

Ozempic’s product information (e.g., EMA materials and UK patient leaflets) describes semaglutide as a GLP-1 analogue used once weekly with specific dose steps.

Why that matters: because “Ozempic = weight loss jab” is an internet shortcut. In clinical and regulatory terms, Ozempic’s primary UK use is for type 2 diabetes management, not weight management.

2) UK indication: Ozempic is for type 2 diabetes (weight loss use is off-label)

The European Medicines Agency summary states Ozempic is used to treat adults with type 2 diabetes whose blood sugar is not satisfactorily controlled, alongside diet and exercise.

UK supply guidance has explicitly warned that:

Ozempic is only indicated for adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise, and
use “including for weight management” is off-label and can put availability for the indicated population at risk.

So when someone says “Ozempic for weight loss,” what they usually mean is:

“I want appetite/weight effects from a GLP-1 medicine,”
but Ozempic is not the UK weight-management brand (Wegovy is).

3) Why people confuse Ozempic with Wegovy

Ozempic and Wegovy both contain semaglutide, but they are positioned differently:

Ozempic: diabetes indication pathway.
Wegovy: weight management pathway; NICE has a dedicated technology appraisal for semaglutide in overweight/obesity management (TA875).

This is why your safest “weight loss” comparison for semaglutide is usually Mounjaro vs Wegovy

4) Dose systems: don’t compare numbers directly

People often try to compare “mg numbers” (like 2mg vs 15mg) and assume higher mg = stronger. That is not a valid comparison across different medicines.

What you can compare safely:

Ozempic has diabetes-focused weekly dosing steps and pen instructions (e.g., starting dose then increases).
Mounjaro’s weight-management use is in its own pathway and product format (tirzepatide). (Your MedCare product page shows multiple strengths available for selection.)

If your goal is weight loss via MedCare, your practical starting point is still the clinician-reviewed pathway on Mounjaro weight loss injection pen.

5) Mechanism: what changes in appetite (high-level)

Semaglutide (Ozempic) is a GLP-1 analogue.
Tirzepatide (Mounjaro) is not the same drug; it has a different mechanism profile (covered simply in How Mounjaro Works for Weight Loss).

If what you want is “how it actually affects hunger, cravings, and fullness,” read:
How Mounjaro Works for Weight Loss.

Comparison table: differences that matter

Difference	Mounjaro	Ozempic	Why it matters in the UK
Active ingredient	Tirzepatide	Semaglutide	Different medicine; not interchangeable
Main UK pathway	Weight management use (authorised)	Type 2 diabetes indication	Weight-loss use of Ozempic is typically off-label
UK supply messaging	—	Off-label weight management use can risk supply for indicated patients	Clinics avoid off-label pathways when alternatives exist
Best “weight-loss brand” comparison	Often compared to Wegovy	Ozempic is commonly confused with Wegovy	Use the correct comparator page: Mounjaro vs Wegovy

If your goal is weight loss in the UK: the clean path

Choose a treatment pathway designed for weight management (not diabetes-only branding).
Complete a clinical assessment so eligibility and safety are checked.
Follow titration plans and lifestyle support to reduce side effects and improve adherence.

For MedCare’s pathway, start here:
Mounjaro weight loss injection pen.

FAQs

Is Ozempic approved for weight loss in the UK?

Ozempic is indicated for type 2 diabetes; UK supply guidance has stated that using it for weight management is off-label and can put availability for indicated patients at risk.

Why does everyone talk about Ozempic for weight loss then?

Because semaglutide can affect appetite and weight, and people often use “Ozempic” as a shorthand for the whole category. In UK guidance and NICE pathways, semaglutide weight management is addressed under Wegovy (TA875).